Leiomyosarcoma (LMS) Completed Phase 2 Trials for Ridaforolimus (DB06233)

Back to Leiomyosarcoma (LMS)

Also known as: LMS - Leiomyosarcoma / Leiomyosarcomas / Leiomyosarcoma / Leiomyosarcoma (morphologic abnormality) / Leiomyosarcoma NOS / Leiomyosarcoma (disorder)

Indication	Status	Phase
DBCOND0118909 (Leiomyosarcoma (LMS))	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT00093080	Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)	Treatment	Ridaforolimus (DB06233)